{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:03Z","timestamp":1791896343273,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Major Projects","award":["2018ZX10301202"],"award-info":[{"award-number":["2018ZX10301202"]}]},{"name":"Innovative Research Team in the National Natural Science Foundation of China","award":["81721002"],"award-info":[{"award-number":["81721002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had potential therapeutic efficacy. We aim to investigate the safety of HBV-TCR-T-cell immunotherapy in advanced HBV-HCC patients who had not met the criteria for liver transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled eight patients with advanced HBV-HCC and adoptively transferred short-lived autologous T cells expressing HBV-specific TCR to perform an open-label, phase 1 dose-escalation study (NCT03899415). The primary endpoint was to evaluate the safety of HBV-TCR-T-cell therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) during the dose-escalation process. The secondary endpoint was to assess the efficacy of HBV-TCR-T-cell therapy by evaluating the anti-tumor responses using RECIST criteria (version 1.1) and the overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Adverse events were observed in two participants among the 8 patients enrolled. Only one patient experienced a Grade 3 liver-related adverse event after receiving a dose of 1\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      HBV-TCR-T cells\/kg, then normalized without interventions with immunosuppressive agents. Among the patients, one achieved a partial response lasting for 27.7\u00a0months. Importantly, most of the patients exhibited a reduction or stabilization of circulating HBsAg and HBV DNA levels after HBV-TCR-T-cell infusion, indicating the on-target effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The adoptive transfer of HBV-TCR-T cells into advanced HBV-HCC patients were generally safe and well-tolerated. Observations of clinical efficacy support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>This study was registered at ClinicalTrials.gov (NCT03899415).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-021-10250-2","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T15:53:41Z","timestamp":1638287621000},"page":"1402-1412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03899415","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fanping","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Tanoto","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Liang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Bao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina Wanju","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai","family":"Lu-En","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarene","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"10250_CR1","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907\u201317.","journal-title":"Lancet"},{"key":"10250_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00008469-200308000-00006","volume":"12","author":"XS Hao","year":"2003","unstructured":"Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, Guo ZY, et al. Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev 2003;12:273\u20139.","journal-title":"Eur J Cancer Prev"},{"key":"10250_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"10250_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"10250_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"10250_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin Cancer Res 2019;25:515\u201323.","journal-title":"Clin Cancer Res"},{"key":"10250_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 2020;71:1247\u201361.","journal-title":"Hepatology"},{"key":"10250_CR8","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-19-3840","volume":"26","author":"M Huang","year":"2020","unstructured":"Huang M, He M, Guo Y, Li H, Shen S, Xie Y, Li X, et al. The influence of immune heterogeneity on the effectiveness of immune checkpoint inhibitors in multifocal hepatocellular carcinomas. Clin Cancer Res 2020;26:4947\u201357.","journal-title":"Clin Cancer Res"},{"key":"10250_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial. Clin Cancer Res 2021;27:1003\u201311.","journal-title":"Clin Cancer Res"},{"key":"10250_CR10","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"key":"10250_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020;21:808\u201320.","journal-title":"Lancet Oncol"},{"key":"10250_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, Zhang Y, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer 2020;9:338\u201357.","journal-title":"Liver Cancer"},{"key":"10250_CR13","doi-asserted-by":"publisher","first-page":"e000987","DOI":"10.1136\/jitc-2020-000987","volume":"8","author":"HHM Ng","year":"2020","unstructured":"Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, et al. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1\/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer 2020;8:e000987.","journal-title":"J Immunother Cancer"},{"key":"10250_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","volume":"148","author":"JH Lee","year":"2015","unstructured":"Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015;148:1383\u201313911386.","journal-title":"Gastroenterology"},{"key":"10250_CR15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3748\/wjg.v10.i8.1146","volume":"10","author":"M Shi","year":"2004","unstructured":"Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10:1146\u201351.","journal-title":"World J Gastroenterol"},{"key":"10250_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/imt.09.47","volume":"1","author":"L Barkholt","year":"2009","unstructured":"Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009;1:753\u201364.","journal-title":"Immunotherapy"},{"key":"10250_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trecan.2020.09.002","volume":"7","author":"M Ecsedi","year":"2020","unstructured":"Ecsedi M, McAfee MS, Chapuis AG. The anticancer potential of T cell receptor-engineered T cells. Trends Cancer 2020;7:48\u201356.","journal-title":"Trends Cancer"},{"key":"10250_CR18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/hep.27406","volume":"60","author":"FS Wang","year":"2014","unstructured":"Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology 2014;60:2099\u2013108.","journal-title":"Hepatology"},{"key":"10250_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477-491e471.","journal-title":"Gastroenterology"},{"key":"10250_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2016.02.005","volume":"64","author":"YT Chiu","year":"2016","unstructured":"Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, Chan LK, Lee JM, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256\u201364.","journal-title":"J Hepatol"},{"key":"10250_CR21","doi-asserted-by":"publisher","first-page":"25075","DOI":"10.18632\/oncotarget.25308","volume":"9","author":"M Furuta","year":"2018","unstructured":"Furuta M, Tanaka H, Shiraishi Y, Unida T, Imamura M, Fujimoto A, Fujita M, et al. Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers. Oncotarget 2018;9:25075\u201388.","journal-title":"Oncotarget"},{"key":"10250_CR22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","volume":"156","author":"AT Tan","year":"2019","unstructured":"Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology. 2019;156:1862-1876e1869.","journal-title":"Gastroenterology"},{"key":"10250_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","volume":"62","author":"W Qasim","year":"2015","unstructured":"Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486\u201391.","journal-title":"J Hepatol"},{"key":"10250_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"10250_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3851\/IMP3280","volume":"24","author":"H Liao","year":"2019","unstructured":"Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy. Antivir Ther 2019;24:105\u201315.","journal-title":"Antivir Ther"},{"key":"10250_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jcv.2010.05.010","volume":"48","author":"Z Xu","year":"2010","unstructured":"Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 2010;48:270\u20134.","journal-title":"J Clin Virol"},{"key":"10250_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jhep.2009.01.026","volume":"50","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Jin B, Zhang JY, Xu B, Wang H, Shi M, Wherry EJ, et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol 2009;50:1163\u201373.","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10250-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T21:05:41Z","timestamp":1638911141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10250-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10250"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10250-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Bertoletti is a co-founder of Lion TCR Pte. Ltd. a biotech company developing T cell receptors for treatment of virus-related cancers and chronic viral diseases. Anthony T. Tan is a scientific consultant for Lion TCR Pte. Ltd. Regina Wanju Wong, Wai Lu-En, Sarene Koh and Tingting Wang are employees of Lion TCR Pte. Ltd. Fanping Meng, Jinfang Zhao, Wei Hu, Si-Yu Wang, Jiehua Jin, Juan Wu, Yuanyuan Li, Lei Shi, Jun-Liang Fu, Shuangjie Yu, Yingjuan Shen, Limin Liu, Junqing Luan, Ming Shi, Yunbo Xie, Chun-Bao Zhou, Ji-Yuan Zhang, Fu-Sheng Wang have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committees of our hospital (2018096D) and fully complied with the Declaration of Helsinki and the Guideline for Good Clinical Practice, informed consent was obtained from eight subjects who participated in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication was obtained from all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal research"}},{"value":"Supporting data for this study are available from the corresponding author and the first author upon reasonable request. The measurements of HBsAg levels were repeated three times.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and plant reproducibility"}}]}}